Company intelligence / Profile preview

Novag

Schlieren, Switzerland

Ownership: Private
Development stage: Other

Overview

Advancing NG004 in Phase 1b trial for acute spinal cord injury (first patient dosed January 2025); preparing IND for NG050 in diabetic retinopathy (Phase 1b planned end 2025). Preclinical data show enhanced nerve repair and functional recovery by blocking Nogo-A receptor.[1][3][5][7]

Therapeutic areas: OphthalmologyNeurology
Modalities: Monoclonal antibody
Industry: Biotech

Beyond the preview

Go deeper on Novag.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novag.

Explore the full profile